Entasis Therapeutics Holdings Inc. (ETTX): Price and Financial Metrics


Entasis Therapeutics Holdings Inc. (ETTX)

Today's Latest Price: $2.77 USD

0.06 (2.21%)

Updated May 29 4:00pm

Add ETTX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ETTX Stock Summary

  • ETTX's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.3 -- higher than merely 5.58% of US-listed equities with positive expected earnings growth.
  • Entasis Therapeutics Holdings Inc's stock had its IPO on September 26, 2018, making it an older stock than merely 2.85% of US equities in our set.
  • The ratio of debt to operating expenses for Entasis Therapeutics Holdings Inc is higher than it is for about only 6.62% of US stocks.
  • If you're looking for stocks that are quantitatively similar to Entasis Therapeutics Holdings Inc, a group of peers worth examining would be CLDX, NOVN, ACIU, ORMP, and UMRX.
  • Visit ETTX's SEC page to see the company's official filings. To visit the company's web site, go to www.entasistx.com.
ETTX Daily Price Range
ETTX 52-Week Price Range

ETTX Stock Price Chart More Charts


ETTX Price/Volume Stats

Current price $2.77 52-week high $9.25
Prev. close $2.71 52-week low $1.75
Day low $2.69 Volume 90,567
Day high $2.85 Avg. volume 22,764
50-day MA $2.64 Dividend yield N/A
200-day MA $4.81 Market Cap 40.48M

Entasis Therapeutics Holdings Inc. (ETTX) Company Bio


Entasis Therapeutics Inc. discovers and develops antibacterials to fight diseases caused by multidrug-resistant bacteria. It offers ETX2514, a broad-spectrum and potent inhibitor of class A, C, and D beta-lactamases that has activity against Acinetobacter baumannii, a gram-negative bacterium that causes severe infections, which are associated with high mortality; ETX0914, a novel oral antibiotic for the treatment of uncomplicated gonorrhea; and a drug discovery platform that focuses on developing novel antibacterials targeting serious gram-negative infections, such as pneumonia, infections of the blood, urinary tract infections, and infections following surgery. Entasis Therapeutics Inc. has strategic development collaboration with Zai Lab Limited. The company was founded in 2015 and is based in Waltham, Massachusetts. Entasis Therapeutics Inc. operates as a subsidiary of AstraZeneca PLC.


ETTX Latest News Stream


Event/TimeNews Detail
Loading, please wait...

ETTX Latest Social Stream


Loading social stream, please wait...

View Full ETTX Social Stream

Latest ETTX News From Around the Web

Below are the latest news stories about Entasis Therapeutics Holdings Inc that investors may wish to consider to help them evaluate ETTX as an investment opportunity.

Analysts Suggest Buying These 2 Falling Knives

Their share prices are predicted to buonce back strongly Continue reading...

Yahoo | May 18, 2020

Entasis Therapeutics Reports First Quarter 2020 Financial Results and Business Update

WALTHAM, Mass., May 07, 2020 -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel.

Yahoo | May 7, 2020

Entasis Therapeutics Completes Initial Closing of $35M Private Placement with Innoviva

Entasis Therapeutics Holdings Inc. (ETTX) (“Entasis”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that it has completed the initial $3.3 million closing of a $35 million common stock and warrant securities investment with Innoviva Inc. (INVA) ("Innoviva"), signed on April 12, 2020. Upon satisfaction of certain closing conditions, Innoviva will purchase the balance of the $35 million in Entasis common stock and warrant securities in a second closing anticipated later in the second quarter of 2020 (excluding any consideration payable upon exercise of warrants). Entasis plans to use the proceeds from the offering to support the continued development of its novel pipeline of pathogen-targeted antibac...

Yahoo | April 22, 2020

Earnings Release: Here's Why Analysts Cut Their Entasis Therapeutics Holdings Inc. Price Target To US$14.50

There's been a major selloff in Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) shares in the week since it released...

Yahoo | March 13, 2020

Entasis Therapeutics Reports Full Year 2019 Financial Results and Business Update

WALTHAM, Mass., March 11, 2020 -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of.

Yahoo | March 11, 2020

Read More 'ETTX' Stories Here

ETTX Price Returns

1-mo 1.47%
3-mo -44.66%
6-mo -43.47%
1-year -54.96%
3-year N/A
5-year N/A
YTD -44.27%
2019 22.11%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8672 seconds.